MedPath
NMPA Approval

Cefprozil for Suspension

国药准字H20253211

January 14, 2025

Drug Information

头孢丙烯干混悬剂

口服混悬剂

1.25g(按C₁₈H₁₉N₃O₅S计)

化学药品

January 14, 2025

Company Information

Applicant Company

深圳市龙华新区观澜高新园区澜清一路16号

Manufacturing Company

深圳市龙华新区观澜高新园区澜清一路16号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

头孢丙烯干混悬剂 - NMPA 批准文号 | MedPath